The YCCC requests continued support for grant related activities that include 9 shared resources, 14 established research programs, 1 developing program and a new clinical trials protocol review and development system. These programs are managed under the direction of four associate directors, working in conjunction with the Director, and an Associate Director, and his administrative staff in four areas: Basic Science, Clinical Science, and Cancer Prevention Research, and Community Research. An Associate Director of Education oversees the Education and training programs of the center. We request continued support for this senior leadership and leaders of established research programs, for planning and evaluation, and developmental funds, and administration. Interdisciplinary coordination in the clinical areas is facilitated by the use of disease oriented units in Breast, GU, GI and Head and Neck cancers; Melanoma, Lymphomas, Brain tumor and a support unit on bone marrow transplantation. Yale's extraordinary depth in Molecular Biology provides focus for the centers translational research. The clinical Research programs are organized around major specialties and have been augmented in this grant cycle by an expanded emphasis on the use of new technology to overcome the major limitations of cancer treatment and prevention by transferring through the means of a shared resource, formerly the tissue retrieval resource, and now the Critical technologies Shared Resource, the capability to include sophisticated molecular technologies in clinical trials in diagnosis, treatment and Prevention, to allow the proper preservation of tissue, and the measurement of both structure and function to correlate with outcome. A new shared resource since the last grant cycle, Clinical Pharmacology, takes advantage of the YCCC's strength in Cancer Pharmacology. Other shared resources include, Flow Cytometry, Animal Tumor Models, Tissue Culture/Media Preparation, Mass Spectrometry, a Cesium-13T Irradiator, and a Transgenic Mouse Shared Resource. The basic research programs in Pathology, Molecular Oncology and Development, Molecular Virology and Cell Biology all emphasize research on oncogenes and suppressor oncogenes vis-a-vis the cell signaling systems. The Program in Immunology focuses on regulation of antigen and growth control processing by T-cells. The Developmental Therapeutics?Chemotherapy Program aims at developing anticancer agents directed at newly identified molecular targets. A developing program in Cancer Genetics will attempt to translate these activities into clinically useful tools.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016359-20
Application #
2086466
Study Section
Cancer Center Support Review Committee (CCS)
Project Start
1977-12-01
Project End
1997-06-30
Budget Start
1994-08-03
Budget End
1995-06-30
Support Year
20
Fiscal Year
1994
Total Cost
Indirect Cost
Name
Yale University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
082359691
City
New Haven
State
CT
Country
United States
Zip Code
06520
Bonazzoli, Elena; Predolini, Federica; Cocco, Emiliano et al. (2018) Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer. Clin Cancer Res 24:4845-4853
Villarroel-Espindola, Franz; Yu, Xiaoqing; Datar, Ila et al. (2018) Spatially Resolved and Quantitative Analysis of VISTA/PD-1H as a Novel Immunotherapy Target in Human Non-Small Cell Lung Cancer. Clin Cancer Res 24:1562-1573
Wadia, Roxanne J; Stolar, Marilyn; Grens, Clarice et al. (2018) The prevention of chemotherapy induced peripheral neuropathy by concurrent treatment with drugs used for bipolar disease: a retrospective chart analysis in human cancer patients. Oncotarget 9:7322-7331
De Feyter, Henk M; Behar, Kevin L; Corbin, Zachary A et al. (2018) Deuterium metabolic imaging (DMI) for MRI-based 3D mapping of metabolism in vivo. Sci Adv 4:eaat7314
Ventura, Alessandra; Vassall, Aaron; Robinson, Eve et al. (2018) Extracorporeal Photochemotherapy Drives Monocyte-to-Dendritic Cell Maturation to Induce Anticancer Immunity. Cancer Res 78:4045-4058
Xiao, Qian; Wu, Jibo; Wang, Wei-Jia et al. (2018) DKK2 imparts tumor immunity evasion through ?-catenin-independent suppression of cytotoxic immune-cell activation. Nat Med 24:262-270
Jagannath, Sundar; Laubach, Jacob; Wong, Ellice et al. (2018) Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study. Br J Haematol 182:495-503
Liu, Xiaoni; Zhang, Shang-Min; McGeary, Meaghan K et al. (2018) KDM5B Promotes Drug Resistance by Regulating Melanoma Propagating Cell Subpopulations. Mol Cancer Ther :
Chae, Wook-Jin; Bothwell, Alfred L M (2018) Therapeutic Potential of Gene-Modified Regulatory T Cells: From Bench to Bedside. Front Immunol 9:303
Kim, Hanseul; Keum, NaNa; Giovannucci, Edward L et al. (2018) Garlic intake and gastric cancer risk: Results from two large prospective US cohort studies. Int J Cancer 143:1047-1053

Showing the most recent 10 out of 675 publications